



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : CRIPPS et al. Confirmation No: 1830
Appl. No. : 10/774,393
Filed : February 10, 2004
Title : PHARMACEUTICAL FORMULATION OF FLUTICASONE
: PROPIONATE

TC/A.U. : 1616
Examiner : M Haghighatian

Docket No.: : CRIP3001C3/REF
Customer No: : 23364

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is being submitted in the above-identified patent application as the required submission with an RCE. A listing of these documents is submitted herewith on Form PTO-1449. The U.S. Patents are listed but copies are no longer required and therefore only the non-patented reference is herewith enclosed. These references were cited in co-pending application U.S. 10/630,655 and are submitted herewith in compliance with the duty of disclosure.

The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.

Respectfully submitted,

BACON & THOMAS, PLLC

By: Richard E. Fichter
Richard E. Fichter
Registration No. 26,382

625 Slaters Lane, 4th Fl.
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080
REF:kdd
IDS.wpd
June 21, 2005

B/O Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant	Att'y. Docket Number	Serial Number
	CRIP3001C3/REF	10/774,393
	Applicant	
	CRIPPS et al.	
	Filing Date	Group
	February 10, 2004	1616

U.S. Patent Documents

Examiner Initial	Document Number	Date	Patentee/Applicant	Class	Subclass	Filing Date if Appropriate
	6,309,623	10/2001	Weers et al.	424	45	
	5,914,122	06/1999	Otterbeck et al.	424	434	

Foreign Patent Documents

Examiner Initial	Document Number	Publication Date	Country/Agency	Class	Subclass	Translation	
						Yes	No

Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

	S.S. Davis, G. Elson and J. Whitmore, "Physico-Chemical Studies on Aerosol Solutions for Drug Delivery II, Water-Propylene Glycol-Ethanol Systems", International Journal of Pharmaceuticals, 1 (1978), 85-93.

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.